Concepedia

Author

Tetsuhiko Shirasaka

Taiho Pharmaceutical (Japan)

Also Known As

Shirasaka, T., T Shirasaka, T. Shirasaka, Tetsuhiko SHIRASAKA, Tetsuhiko Shirasaka

130

Publications

4K

Citations

24

H-Index

67

Concepts

All Affiliations

Taiho Pharmaceutical (Japan)Kitasato UniversityKitasato Institute HospitalOtsuka (Japan)The University of Osaka
TS

About

Tetsuhiko Shirasaka is an author at Taiho Pharmaceutical (Japan) specializing in medicine, pharmacology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

35

2.4K

2

Biochemistry

11

11

817

3

Natural Sciences

8

8

745

4

Health Sciences

5

5

386

5

Biomolecular Engineering

1

1

12

Tetsuhiko Shirasaka

×

45

Publications

3.7K

Citations

24

H-Index

YearCitations

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo,

Anti-Cancer Drugs

1996

819

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

Tetsuhiko Shirasaka, K Nakano, T Takechi,

PubMed

1996

370

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.

Tetsuhiko Shirasaka, Yuji Shimamoto, Masakazu Fukushima

PubMed

1993

350

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

Kunihiko Tatsumi, Masakazu Fukushima, Tetsuhiko Shirasaka,

PubMed

1987

261

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.

Keiji Hirata, N Horikoshi, K Aiba,

PubMed

1999

227

Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.

Setsuro Fujii, Kazuhiro Ikenaka, Masakazu Fukushima,

Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)

1978

185

Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents.

Setsuro Fujii, Shizuo Kitano, Kazuhiro Ikenaka,

PubMed

1979

172

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

Tetsuhiko Shirasaka, Yuji Shimamoto, Hideyuki Ohshimo,

Cancer Chemotherapy and Pharmacology

1993

152

Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas

Tetsuhiko Shirasaka

Japanese Journal of Clinical Oncology

2008

147

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.

M Fukushima, Hirofumi Satake, Junji Uchida,

International Journal of Oncology

1998

105

Page 1